Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.

about

Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.

Item

http://www.wikidata.org/entity/Q53396296

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@en

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@nl

type

Item

label

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@en

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@nl

prefLabel

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@en

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@nl

P1476

Concerning pretreatment ¹⁸F-FD ...... ocally advanced breast cancer.

@en

P2093

David Groheux

http://www.w3.org/2001/XMLSchema#string

Elif Hindié

http://www.w3.org/2001/XMLSchema#string

P2860

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.

Additional value of PET-CT in staging of clinical stage IIB and III breast cancer.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

P2888

s00259-015-3144-0

P304

1801-1803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1007/S00259-015-3144-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280694040

http://www.w3.org/2001/XMLSchema#string

P698

26239284

http://www.w3.org/2001/XMLSchema#string